由 浙江金投盛源股权投资有限公司 撰写的 《合成生物行业&投引策略研究报告》 已发布 ，该报告从技术路径、市场格局、代表企业、产业集群、政策 动向等多维度分析解析，为业内人士提供系统性的行业洞察与投资参考。 完整版 研究报告获取方式： 扫码， 添加小编微信 获取【完整版】 加好友，务必备注： 姓名+公司+职务 研究报告部分内容节选： 浙江会设盛调股权投资有限公 金投盛源成立于2023年6月,注册资本2000万元,是浙江省创新投资集团旗下的市场化股权投资平台 主导、联合金浦产业投资基金管理有限公司、苏州工业园区元天原点创业投资管理有限公司、中保投资有 限责任公司、嘉兴浙华嘉融投资管理有限公司等国内知名投资机构，共同出资组建的市场化、专业化股权 投资平台。 公司致力于服务浙江省级政府产业基金运作提质增效,全力助推浙江省打造现代化产业体系,借鉴股 东方的优秀理念和机制、整合贯通各合作方的产业和资本资源,通过守正创新、快速迭代,持续打造具有 金投盛源自身特色的投资运作管理体系。公司主要围绕新材料、新技术、生物医药等领域开展股权投资, 已投资基金的基金总规模合计超100亿元，并将在基金设立组建、重大项目投资、优质项目招 ...

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to be approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of bio-based long-chain dicarboxylic acid since 2003, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, particularly in the context of AI and automation [15][16].

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to reach approximately 10 billion yuan in 2024 and continue to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of long-chain dicarboxylic acids through biological methods, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, particularly in the context of AI and automation [15][16].

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to be approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of bio-based long-chain dicarboxylic acids since 2003, breaking the monopoly of chemical synthesis methods [7]. - Ginkgo Bioworks, established in 2008, has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, particularly in the context of AI and automation [15][16].

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to reach approximately 10 billion yuan in 2024 and continue to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of bio-based long-chain dicarboxylic acids since 2003, breaking the monopoly of chemical synthesis methods [7]. - Ginkgo Bioworks, established in 2008, has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, particularly in the context of AI and automation [15][16].

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan [6][34]. - Jintou Shengyuan aims to enhance the operation of provincial government industrial funds and support the establishment of a modern industrial system in Zhejiang [34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to be approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of long-chain dicarboxylic acids through biological methods, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research and product offerings, particularly in the context of AI and automation [15][16].

Group 1 - The 6th Bio-Manufacturing Industrial Conference will take place on December 2, 2025, at the Guangming Cultural and Art Center in Shenzhen, focusing on synthetic biological manufacturing [2][4][40] - The conference is organized by several prominent institutions, including the Chinese Society of Biotechnology and the Shenzhen Institutes of Advanced Technology [2][39] - The event aims to gather key players from industry, academia, research, and investment sectors to discuss trends and insights in bio-manufacturing [3][45] Group 2 - A second batch of distinguished guests has been announced, featuring experts from various fields who will engage in deep discussions and share valuable insights [3][45] - The conference will include multiple forums and sessions, covering topics such as bio-manufacturing in the Guangdong-Hong Kong-Macao Greater Bay Area, pharmaceuticals, agriculture, and automation [49][50] - Evening sessions will feature project roadshows highlighting emerging forces in the bio-manufacturing industry [50]

Core Viewpoint - The establishment of the "Shenzhen University-Ningbo Enzyme Bioengineering Co., Ltd. Joint Laboratory for Computational Protein" marks a significant collaboration aimed at advancing AI-driven synthetic biology research and its industrial applications in pharmaceuticals, energy, and agriculture [1][4][6]. Group 1: Joint Laboratory Focus - The joint laboratory will focus on AI-driven synthetic biology research, emphasizing protein design and optimization, high-performance industrial enzyme development, and the application of these technologies in various industries [4][5]. - Key research directions include computational protein design, computer simulation and intelligent optimization of biosynthetic pathways, and talent cultivation in AI-integrated enzyme engineering [5][6]. Group 2: Industry Impact - The introduction of AI technology is expected to revolutionize traditional research methods in protein design, metabolic engineering, and biosynthesis, aiming to create a programmable and scalable intelligent bio-manufacturing platform [6]. - The collaboration is seen as a model for industry-academia cooperation, leveraging the research strengths of Shenzhen University and the industrial capabilities of Ningbo Enzyme Bioengineering to promote practical applications of synthetic biology [6][7]. Group 3: Company Background - Shenzhen University, established as a new research-oriented institution in 2024, focuses on foundational and cutting-edge scientific research and the cultivation of innovative talents [6][7]. - Ningbo Enzyme Bioengineering Co., Ltd. is a leading synthetic biology company in China, possessing proprietary technologies in protein design and enzyme engineering, with capabilities spanning from laboratory research to industrial production [7]. Group 4: Future Prospects - The collaboration signifies a new phase in AI-driven bio-manufacturing, contributing to the high-quality development of China's bio-economy [8].

Core Viewpoint - The company, Shengquan Group, reported significant growth in its half-year results for 2025, with a revenue increase of 15.67% and a net profit increase of 51.19%, indicating strong performance driven by high-demand sectors such as advanced electronic materials and new energy vehicle materials [2][4]. Financial Performance - For the first half of 2025, Shengquan Group achieved an operating income of 5.35 billion yuan, up from 4.63 billion yuan in the same period last year, marking a growth of 15.67% [3]. - The net profit attributable to shareholders reached 500.94 million yuan, a 51.19% increase compared to 331.32 million yuan in the previous year [3]. - Total assets at the end of the reporting period were 162.80 billion yuan, with total liabilities of 58.05 billion yuan, resulting in a debt-to-asset ratio of 35.65% [2]. Reasons for Performance Growth - The advanced electronic materials business experienced explosive growth, particularly in PPO resin, driven by a surge in global AI server demand, positioning the company as a key supplier in the chip packaging and server PCB material market [4]. - The penetration rate of global new energy vehicles has crossed a critical point, leading to geometric growth in demand for power battery materials. The company has developed high-performance and cost-effective porous carbon materials for mainstream battery supply chains [4]. - The company has also focused on developing high-end customized products for traditional businesses, gaining market recognition [4]. - The biomass industry has seen capacity release and new product breakthroughs, with stable operations at the Daqing base and increased sales of xylitol and L-arabinose at the Junqiu base [4]. Business Segment Performance - In the first half of 2025, the advanced electronic materials and battery materials segment generated revenue of 846 million yuan, a 32.43% increase year-on-year, with sales volume reaching 40,100 tons, up 14.90% [5]. - The synthetic resin products segment reported revenue of 2.81 billion yuan in the first half of 2025, a 10.35% increase, with sales volume of 391,800 tons, up 15.48% [7]. - The biomass industry is projected to achieve revenue of 9.56 billion yuan in 2024, reflecting an 11.74% increase from 2023 [10]. Future Outlook - Shengquan Group is expected to surpass the 10 billion yuan revenue mark for the first time in 2024, with projections indicating that 2025 revenue could exceed 11 billion yuan [10].

Core Viewpoint - The article highlights the participation of Huo Tong Instruments at the SynBioCon 2025, emphasizing its leadership in high-end reaction kettle and customized reaction synthesis equipment in China [2][21]. Company Overview - Huo Tong Instruments is headquartered in Shanghai, China, with branches in Hefei, Beijing, Guangzhou, and Taiyuan. The company possesses multiple technical patents and has extensive experience in providing complete solutions from design to manufacturing [5]. - The company integrates research and development, production, and sales, supported by a team of experienced technical personnel and professional after-sales service [5]. Product Summary - **100L Polylactic Acid Reaction Device**: A continuous flow reaction device characterized by continuous feeding, reaction, and discharging, offering high mass and heat transfer efficiency, stability, and safety [6]. - **Resin Synthesis Device**: Features dual gas inlets, high-quality flow meters for accurate measurement, and a deep-cooling reaction kettle with a design temperature of -120°C, along with a user-friendly touchscreen control system [9]. - **Esterification and Polycondensation Reaction Device**: Customizable according to client needs, including high vacuum and high-temperature discharge capabilities [11]. - **Dynamic Tubular Reactor**: Designed for high shear dispersion with a dual heat exchange structure, offering a design pressure of 0-2 MPa and temperature range of -15 to 200°C [14]. - **Intelligent Continuous Flow Platform**: A self-developed system centered around micro-reactors, capable of an annual production capacity of approximately 50 tons [17]. Event Details - The SynBioCon 2025 will take place from August 20-22, 2025, in Ningbo, Zhejiang, focusing on AI and bio-manufacturing, green chemistry, new materials, future food, and agriculture [21]. - The event will include various activities such as a youth forum, high-level discussions, and a closed-door seminar on the "2025 AI Empowering Bio-Manufacturing Industry Innovation Development Blue Book" [21][22][23].